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Introduction: The Surviving Sepsis Campaign guidelines recommend goal-directed therapy (GDT) for the early
resuscitation of patients with sepsis. However, the findings of the ProCESS (Protocolized Care for Early Septic Shock) trial
showed no benefit from GDT for reducing mortality rates in early septic shock. We performed a meta-analysis to
integrate these findings with existing literature on this topic and evaluate the effect of GDT on mortality due to sepsis.
Methods: We searched the PubMed, Embase and CENTRAL (Cochrane Central Register of Controlled Trials) databases
and reference lists of extracted articles. Randomized controlled trials comparing GDT with standard therapy or usual
care in patients with sepsis were included. The prespecified primary outcome was overall mortality.
Results: In total, 13 trials involving 2,525 adult patients were included. GDT significantly reduced overall mortality in the
random-effects model (relative risk (RR), 0.83; 95% confidence interval (CI), 0.71 to 0.96; P =0.01; I2 = 56%). Predefined
subgroup analysis according to the timing of GDT for resuscitation suggested that a mortality benefit was seen only in
the subgroup of early GDT within the first 6 hours (seven trials; RR, 0.77; 95% CI, 0.67 to 0.89; P =0.0004; I2 = 40%), but
not in the subgroup with late or unclear timing of GDT (six trials; RR, 0.92; 95% CI, 0.69 to 1.24; P =0.59; I2 = 56%). GDT
was significantly associated with the use of dobutamine (five trials; RR, 2.71; 95% CI, 1.20 to 6.10; P =0.02).
Conclusions: The results of the present meta-analysis suggest that GDT significantly reduces overall mortality in
patients with sepsis, especially when initiated early. However, owing to the variable quality of the studies, strong and
definitive recommendations cannot be made.Introduction
Sepsis is a systemic response to infection, which may pro-
gress to severe sepsis and septic shock [1]. Severe sepsis
and septic shock represent global problems with a high
economic burden. In the United States, more than
750,000 people experience severe sepsis each year, with a
short-term mortality of 20% to 30%, reaching up to 50%
when shock is present [2,3]. Therefore, numerous thera-
peutic strategies that aimed at reducing mortality in these
patients have been investigated. However, most of them
have not led to significant reductions in mortality [4].
Goal-directed therapy (GDT) has been shown to substan-
tially improve clinical outcomes in surgical patients [5].
Two important aspects of a GDT protocol include early* Correspondence: jingchenliu1964@sina.cn
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specific (hemodynamic) targets. The Surviving Sepsis
Campaign guidelines recommend GDT for the early re-
suscitation of patients with sepsis [1], which is based
largely upon the results of the Rivers et al. trial, in which
the researchers reported a 16% absolute reduction in mor-
tality among patients with severe sepsis or septic shock
who received early GDT compared to standard therapy
[6]. However, in a recent study, this approach was chal-
lenged [7], with no benefit shown when GDT was com-
pared to standard therapy. However, initiating therapy
early rather than late in the course of critical illness re-
mains a logical clinical goal. In the context of this situ-
ation, we systematically reviewed all trials of GDT in
patients with sepsis and performed a meta-analysis, focus-
ing on the early initiation of the protocol and its effect on
mortality.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Ethical approval and patient consent were not required,
because we conducted a meta-analysis of previously pub-
lished studies. We followed the recommendations of the
Cochrane Handbook for Systematic Reviews of Interven-
tions to carry out the study [8] and follow the PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) statement to report our meta-analysis [9].Search strategy
Electronic searches were conducted in the PubMed,
Embase and Cochrane Central Register of Controlled
Trials (CENTRAL) databases. Search terms included
“goal directed,” “goal oriented,” “goal target,” “cardiac
output,” “cardiac index,” “oxygen delivery,” “oxygen con-
sumption,” “cardiac volume,” “stroke volume,” “fluid ther-
apy,” “fluid loading,” “fluid administration,” “optimization,”
“optimization,” “supranormal” and “sepsis,” “severe sepsis,”
“septic shock,” “septicemia,” “septicaemia,” “pyohemia,” “py-
aemia” and “pyemia.” There was no language restriction
placed on the searches. Each database was searched from in-
ception to April 2014. Additionally, reference lists in the ar-
ticles chosen for inclusion, and the reference lists of
previous reviews were screened to identify other potentially
eligible trials.Inclusion criteria
We included trials with the following characteristics:
1. Population: Adult patients with one or more of the
following characteristics were eligible for inclusion:
sepsis, severe sepsis or septic shock. Adults were
defined as being of a legal age for consent in the
country where the trial was conducted. Studies that
included sepsis secondary to noninfectious causes
were excluded.
2. Intervention: The intervention had to be GDT,
defined as an explicit protocol encompassing the use
of hemodynamic monitoring and manipulation of
hemodynamic parameters to achieve predetermined
hemodynamic endpoints.
3. Control: The control group had to have received
standard therapy or usual care.
4. Outcomes: The overall mortality rate had to be the
outcome measured.
5. Type of study: The studies had to be randomized
controlled trials (RCTs).
We included studies that randomized a mixed popula-
tion of critically ill patients when a septic subpopulation
that met our inclusion criteria was defined; that is, the
patients with sepsis constituted a subgroup of the trial
population.Data extraction
We extracted data using a standardized data collection
form. Discrepancies in collected data were addressed
through team consensus. The following information was
extracted from each trial: first author, year of publica-
tion, number of patients (GDT and control), study popu-
lation, clinical setting, goals in GDT and control groups,
timing of GDT, mortality endpoint, study design (patient
selection and concealment) and outcome data (overall
mortality and dobutamine use).
Outcomes and definitions
The prespecified primary outcome was overall mortality.
If the study authors reported mortality at one time
point, we used the only data used for analysis. If the
study authors reported mortality at more than one time
point, we used hospital mortality preferentially. Second-
ary outcomes included overall mortality in the early-
initiated GDT (that is, within the first 6 hours) versus
GDT and dobutamine use initiated later.
Assessment of risk of bias
We used the Cochrane Collaboration tool to assess the
risk of bias of individual study and with bias domains
across studies [8,10]. Two investigators (WJG and FW)
subjectively reviewed all studies and assigned a value of
“high,” “low” or “unclear” to the following domains: ran-
dom sequence generation, allocation concealment, blind-
ing of participants and personnel, blinding of outcome
assessment, incomplete outcome data, selective report-
ing and other bias. Trials with high risk of bias for any
one or more key domains were considered to be at high
risk of bias. Trials with low risk of bias for all key do-
mains were considered to be at low risk of bias. Other-
wise, they were considered to have an unclear risk of
bias [10].
Statistical analysis
We estimated the relative risk (RR) with 95% confidence
interval (CI) for dichotomous outcomes. Statistical hetero-
geneity across studies was tested by using the I2 statistic
[11,12]. Heterogeneity was suggested if the P-value was
≤0.10. I2 values of 0 to 24.9%, 25% to 49.9%, 50% to 74.9%
and 75% to 100% were considered zero, low, moderate and
high thresholds for statistical heterogeneity, respectively
[11,12]. Clinical heterogeneity could not be excluded, so the
more conservative random-effects model [13] (Mantel–
Haenszel method) was used. Predefined subgroup analysis
was conducted according to the timing of GDT for resusci-
tation (early being within the first 6 hours versus late or
unclear being outside the first 6 hours or unclear timing). In
addition, we performed post hoc subgroup analyses accord-
ing to risk of bias (low versus unclear), sample size (≥100
versus <100) and setting (emergency department versus
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a single study on the overall pooled estimate by omitting
one study in each step. The potential for bias was assessed
by inspection of a funnel plot and Egger’s test [14]. The
results were considered statistically significant at two-sided
P-values <0.05. All statistical analyses were performed using
RevMan 5.2 software (The Nordic Cochrane Centre,
Copenhagen, Denmark).
Quality of evidence
We evaluated the quality of the evidence by using the
Grades of Recommendation, Assessment, Development
and Evaluation (GRADE) approach [15]. In addition, the
GRADEprofiler 3.6 software (The Nordic Cochrane Centre)
was used to create the evidence profile. The GRADEWork-
ing Group grades of evidence used were as follows:
(1)High quality: Further research is very unlikely to
change our confidence in the estimate of effect.
(2)Moderate quality: Further research is likely to have
an important impact on our confidence in the
estimate of effect and may change the estimate.
(3)Low quality: Further research is very likely to have
an important impact on our confidence in the
estimate of effect and is likely to change the
estimate.Figure 1 Flow diagram showing results of search and reasons for exc(4)Very low quality: We are very uncertain about the
estimate.
Results
In the initial search, we identified 1,263 records. After exam-
ination of the titles and abstracts, there were 30 potentially
eligible studies assessed for inclusion. After application of
the inclusion criteria, 13 RCTs [6,7,16-26] were included in
the meta-analysis. The study flow diagram, including the
reasons for exclusion of studies, is shown in Figure 1.
Study characteristics
The characteristics of the included trials are presented in
Table 1. These trials were published between 1992 and
2014. The sample size of the trials ranged from 34 to 895,
with a total of 2,525 patients comprising 1,299 in the
GDT group and 1,226 in the control group. Eleven trials
were conducted in the intensive care unit [16-26], and the
remaining two were conducted in the emergency depart-
ment [6,7]. Four trials were published in Chinese [23-26],
and the other nine trials were in English [6,7,16-22]. Early
GDT for resuscitation within the first 6 hours was re-
ported in seven trials [6,7,16,21,22,24-26], late GDT for re-
suscitation outside the first 6 hours was assessed in one
trial [23] and unclear timing of GDT was described in five
trials [17-21]. Overall mortality was reported in all trialslusion of studies. RCT, Randomized controlled trial.
Table 1 Characteristics of included randomized controlled trialsa
Study Year No. of patients with
sepsis (GDT/control)
Study population Clinical
setting
Goals in GDT group Goals in control group Timing of
GDT
Mortality
endpoint
Tuchschmidt et al. [16] 1992 51 (26/25) Adult patients with septic shock ICU CI ≥6 L/min/m2 CI ≥3 L/min/m2 Within the
first 6 hr
14 days
SBP ≥90 mmHg SBP ≥90 mmHg
Yu et al. [17] 1993 52 (30/22) Adult patients with sepsis or septic
shock
ICU DO2I >600 ml/min/m
2 DO2I 450 to 550 ml/min/m
2 Unclear 30 days
(septic subpopulation) SBP >100 mmHg SBP >100 mmHg
Hayes et al. [18] 1994 47 (24/23) Adult patients with septic shock ICU CI ≥4.5 L/min/m2 Usual care Unclear Hospital
(septic subpopulation) DO2 600 ml/min/m
2
VO2 > 170 ml/min/m
2
Gattinoni et al. [19] 1995 181 (124/57) Adult patients with septic shock or
septic syndrome
ICU CI ≥4.5 L/min/m2 or
SvO2 ≥ 70%
CI 2.5 to 3.5 L/min/m2 Unclear ICU
MAP ≥65 mmHg
(septic subpopulation) MAP ≥65 mmHg CVP 8 to 12 mmHg
CVP 8 to 12 mmHg UO ≥0.5 ml/kg/hr
UO ≥0.5 ml/kg/h
Yu et al. [20] 1998 87 (58/29) Adult patients with sepsis, severe
sepsis or septic shock
ICU DO2I >600 ml/min/m
2 DO2I 450 to 550 ml/min/m
2 Unclear ICU
SBP ≥100 mmHg SBP ≥100 mmHg
(septic subpopulation) SvO2 > 65% SvO2 > 65%
UO >50 ml/hr UO >50 ml/hr
Alía et al. [21] 1999 63 (31/32) Adult patients with severe sepsis or
septic shock
ICU DO2I >600 ml/min/m
2 DO2I >330 ml/min/m
2 Unclear ICU
MAP >60 mmHg MAP >60 mmHg
Rivers et al. [6] 2001 263 (130/133) Adult patients with severe sepsis,
septic shock or sepsis syndrome
ED SvO2 ≥ 70% CVP 8 to 12 mmHg Within the
first 6 hr
Hospital
CVP 8 to 12 mmHg MAP 65 to 90 mmHg
MAP 65 to 90 mmHg UO ≥0.5 ml/kg/hr
UO ≥0.5 ml/kg/hr
Lin et al. [22] 2006 224 (108/116) Adult patients with septic shock ICU CVP 8 to 12 mmHg Usual care Within the
first 6 hr
Hospital
MAP ≥65 mmHg
UO ≥0.5 ml/kg/hr
Wang et al. [23] 2006 34 (16/17) Adult patients with septic shock ICU SvO2 ≥ 70% MAP ≥65 mmHg Within the
first 6 to
10 hr
14 days
CVP 8 to 12 mmHg UO ≥0.5 ml/kg/hr
MAP ≥65 mmHg
UO ≥0.5 ml/kg/hr
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Table 1 Characteristics of included randomized controlled trialsa (Continued)
Chen et al. [24] 2007 123 (58/65) Adult patients with severe sepsis ICU ScvO2≥ 70% CVP 8 to 12 mmHg Within the
first 6 hr
ICU
(septic subpopulation) CVP 8 to 12 mmHg MAP ≥65 mmHg
MAP ≥65 mmHg UO ≥0.5 ml/kg/hr
UO ≥0.5 ml/kg/hr
He et al. [25] 2007 203 (98/105) Adult patients with septic shock ICU ScvO2 or SvO2 ≥ 70% Usual care Within the
first 6 hr
Hospital
CVP 8 to 12 mmHg
MAP ≥65 mmHg
UO ≥0.5 ml/kg/hr
Yan et al. [26] 2010 303 (157/146) Adult patients with severe sepsis or
septic shock
ICU ScvO2≥ 70% CVP 8 to 12 mmHg Within the
first 6 hr
ICU
CVP 8 to 12 mmHg SBP >90 mmHg
SBP >90 mmHg MAP ≥65 mmHg
MAP ≥65 mmHg UO ≥0.5 ml/kg/hr
UO ≥0.5 ml/kg/hr
ProCESS [7] 2014 895 (439/456) Adult patients with septic shock ED ScvO2≥ 70% Usual care Within the
first 6 hr
Hospital
CVP 8 to 12 mmHg
MAP 65 to 90 mmHg
UO ≥0.5 ml/kg/hr
aCI, Cardiac index; CVP, Central venous pressure; DO2, Oxygen delivery; DO2I, Oxygen delivery index; ED, Emergency department; GDT, Goal-directed therapy; ICU, Intensive care unit; MAP, Mean arterial pressure;
ProCESS, Protocolized Care for Early Septic Shock; SIRS, Systemic inflammatory response syndrome; SBP, Systolic blood pressure; ScvO2, Central venous oxygen saturation; SvO2, Mixed venous oxygen saturation; UO,
Urine output; VO2, Oxygen consumption.
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Figure 2 Risk of bias summary.
Gu et al. Critical Care 2014, 18:570 Page 6 of 10
http://ccforum.com/content/18/5/570[6,7,16-26], and dobutamine use was described in eight of
them [6,7,16-19,21,22].
Risk of bias in included studies
The details of risk of bias are summarized in Figure 2.
Five trials were judged to be at low risk of bias
[6,7,19,21,22], and eight trials were judged to be
at unclear risk of bias [16-18,20,23-26]. Adequate ran-
domized sequences were generated in eight trials
[6,7,17-19,21,22,26], and the investigators in five
trials reported appropriate allocation concealment
[6,7,19,21,22]. Among the 13 RCTs, none were double-
blinded. However, blinding of patients and clinicians
was extremely difficult in these trials to evaluate a com-
plex intervention such as a GDT protocol, and we
judged that the primary outcome (that is, overall mor-
tality) was not likely to be influenced by lack of
blinding.
Primary outcome: overall mortality
Mortality data were available in all 13 included trials
[6,7,16-26]. The overall mortality data in the GDT and
control groups were 474 (36.5%) of 1,299 and 520 (42.4%)
of 1,226, respectively. Overall, GDT significantly reduced
overall mortality in the random-effects model (RR, 0.83;
95% CI, 0.71 to 0.96; P =0.01; I2 = 56%) (Figure 3). Further
exclusion of any single study did not alter the overall com-
bined RR, which ranged from 0.80 (95% CI, 0.69 to 0.93)
to 0.85 (95% CI, 0.73 to 0.98). The results of subgroup
analyses are presented in Table 2.
Secondary outcomes
Predefined subgroup analysis according to the timing of
GDT for resuscitation suggested that a mortality benefit
was seen only in the subgroup in early GDT within the
first 6 hours (seven trials; RR, 0.77; 95% CI, 0.67 to 0.89;
P =0.0004; I2 = 40%) (Figure 4), but not in the subgroup
with late or unclear timing of GDT (six trials; RR, 0.92;
95% CI, 0.69 to 1.24; P =0.59; I2 = 56%) (Figure 4).
In five trials, the investigators reported available data
on dobutamine use [6,7,16,21,22]. In those trials, GDT
was significantly associated with dobutamine use (RR,
2.71; 95% CI, 1.20 to 6.10; P =0.02; I2 = 86%).
Publication bias
We detected no evidence of publication bias by assessing
funnel plot either visually (Figure 5) or statistically (P =0.367
by Egger test).
GRADE profile evidence
We found that GRADE Working Group grades of evi-
dence were low for overall mortality, moderate for mortal-
ity in early GDT (within the first 6 hours for resuscitation)and very low for dobutamine use. An additional .doc file
shows these data in more detail (see Additional file 1).
Discussion
Our meta-analysis of 13 RCTs showed that GDT was as-
sociated with a 17% RR reduction on overall mortality in
patients with sepsis. This mortality benefit was present in
studies in which GDT was started early, but not when ini-
tiated late or when the timing of GDT was unclear. In
addition, GDT was significantly associated with dobuta-
mine use.
Despite these findings, the effect of GDT remains a
matter of debate, as the most recent and largest trial
Figure 3 Forest plot of the effect goal-directed therapy on overall mortality. GDT, Goal-directed therapy.
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ence in mortality, in contrast to many of the preceding
studies. This could be due to the effect of the rapid accept-
ance of the principal interventions of the Rivers et al.
study [6] and the subsequent Surviving Sepsis Campaign
guidelines, which encompassed all elements of the Rivers
study protocol. This is illustrated by the fact that, in the
ProCESS (Protocolized Care for Early Septic Shock) trial,
all groups received, on average, more than 2 L of fluid
prior to randomization and more than 75% of patients re-
ceived antibiotics before randomization. In addition, the
mortality rate was much lower in the ProCESS trial than
in preceding trials, possibly reflecting the effect of early
diagnosis, fluid resuscitation and initiation of antibiotics
on mortality. As the ProCESS trial, like the Rivers et al.
study, enrolled patients with sepsis in the emergency de-
partment, this effect may have been prominent [27].
Although the current evidence supports the early use of
GDT to improve outcomes in patients with sepsis, theTable 2 Subgroup analyses of overall mortalitya
Subgroups No. of studies No. of pa
All trials [6,7,16-26] 13 2,525
GDT timing
Early [6,7,16,22,24-26] 7 2,062
Late or unclear [17-21,23] 6 463
Risk of bias
Low [6,7,19,21,22] 5 1,626
Unclear [16-18,20,23-26] 8 899
Sample size
≥100 [6,7,19,22,24-26] 7 2,192
<100 [16-18,20,21,23] 6 333
Setting
ED [6,7] 2 1,158
ICU [16-26] 11 1,367
aCI, Confidence interval; ED, Emergency department; GDT, Goal-directed therapy; ICoptimal goals remain uncertain. Currently, the Surviving
Sepsis Campaign guidelines recommend the use of central
venous pressure (CVP), mean arterial pressure, urine out-
put and central venous oxygen saturation (ScvO2) as resus-
citation goals. However, many of these recommendations
have been questioned in recent studies. A recent study [28]
was designed to compare the use of lactate clearance to
ScvO2 as a goal of early (up to 6 hours) sepsis resuscitation.
No significant difference in mortality was found (17% in
the lactate clearance group versus 23% in ScvO2 group).
However, when both normalization of ScvO2 and a rapid
decrease in lactate levels were applied as therapeutic goals
in the early resuscitation of a mixed group of critically ill
patients, including a large subgroup of sepsis patients, mor-
tality was significantly reduced [29]. In addition, in a recent
retrospective study, researchers questioned the CVP end-
point in sepsis resuscitation [30].
Further research is needed before strong and definitive
recommendations can be made regarding the effect oftients RR (95% CI) P-value I2 (%)
0.83 (0.71 to 0.96) 0.01 56
0.77 (0.67 to 0.89) 0.0004 40
0.92 (0.69 to 1.24) 0.59 56
0.92 (0.75 to 1.13) 0.42 67
0.74 (0.62 to 0.89) 0.002 31
0.82 (0.70 to 0.95) 0.01 59
0.81 (0.56 to 1.17) 0.27 61
0.86 (0.52 to 1.44) 0.52 83
0.81 (0.69 to 0.96) 0.01 53
U, Intensive care medicine; RR, Relative risk.
Figure 4 Forest plot of the effect goal-directed therapy on overall mortality according to the timing of treatment. GDT,
Goal-directed therapy.
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currently at least two ongoing RCTs of GDT in patients
with sepsis: the Australasian Resuscitation in Sepsis
Evaluation (ARISE) trial in Australia (ClinicalTrials.gov
ID: NCT00975793) and the Protocolised Management in
Sepsis (ProMISe) trial in the United Kingdom (Current
Controlled Trials number: ISRCTN36307479) [31]. The
results of these ongoing trials should provide further
guidance as to the effect of GDT for resuscitation of pa-
tients with sepsis.Figure 5 Funnel plot of the effect goal-directed therapy on overall mA major strength of the present meta-analysis is its
compliance with the Cochrane handbook methodology
recommendations. We conducted an exhaustive literature
search that included non-English-language articles. Two
authors independently screened all references, included
eligible trials, extracted data information, assessed risk of
bias and performed statistical analyses. Moreover, we
followed the PRISMA statement to report this meta-
analysis and evaluated the quality of the evidence by using
the GRADE approach.ortality. GDT, Goal-directed therapy.
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with sepsis, we performed predefined subgroup ana-
lyses according to the timing of GDT. We also per-
formed post hoc subgroup analyses according to risk
of bias, disease severity, sample size and publication
date. These subgroup analyses based on assessment
of bias and clinically relevant groups may help health
care professionals in clinical decision-making.
Our analysis also has several limitations that must
be taken into consideration when interpreting the re-
sults. First, most of the included trials had a high
risk of bias (Figure 2). The potential importance of
this issue is highlighted by the fact that predefined
subgroup analysis comparing mortality estimates be-
tween trials with low versus unclear risk of bias sug-
gested the mortality benefit is not clearly apparent
among the trials with low risk of bias, although this
subgroup difference was not statistically significant
(P =0.90). Second, there were some differences in
the target populations and protocols of GDT of each
study. These factors may have a potential impact
on our results and may preclude firm conclusions.
Third, different endpoints were used for mortality
evaluation. Because this study was a study-level
meta-analysis, individual patient data were not in-
cluded in the analysis; thus, we could not adjust for
patient-level confounders.
Conclusions
The evidence suggests that GDT significantly reduces
overall mortality in patients with sepsis, especially
when initiated early (within the first 6 hours of ad-
mission). Until the results of ongoing randomized
controlled trials are known, strong and definitive rec-
ommendations cannot be made regarding the effect
of GDT for resuscitation of patients with sepsis.
Key messages
 The Surviving Sepsis Campaign guidelines
recommend GDT for the early resuscitation of
patients with sepsis, but controversies about its
effect remain.
 The recent ProCESS trial has shown no
mortality benefit from GDT in early septic
shock.
 The current evidence, in the aggregate, suggests
that GDT significantly reduces overall mortality
in patients with sepsis, especially when initiated
early (within the first 6 hours of admission).
 Further research is needed before strong and
definitive recommendations can be made regarding
the effect of GDT for resuscitation of patients with
sepsis, and the optimal goals remain uncertain.Additional file
Additional file 1: GRADE summary of findings.
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